Form 8-K

8-K — BioXcel Therapeutics, Inc.

Accession: 0001104659-26-102570

Filed: 2026-08-28

Period: 2026-08-27

CIK: 0001720893

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Bankruptcy or Receivership

Documents

8-K — tm2624233d1_8k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2624233d1_8k.htm · Sequence: 1

false

0001720893

2026-08-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 27, 2026

BioXcel

Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-38410

82-1386754

(State

or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification No.)

555

Long Wharf Drive

New

Haven, CT 06511

(Address of principal executive offices, including

Zip Code)

(475)

238-6837

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed

since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

¨ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

Stock, par value $0.001

BTAI

The Nasdaq

Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive

Agreement.

The information set forth below in Item 1.03

of this Current Report on Form 8-K is incorporated herein by reference.

Item 1.03

Bankruptcy or Receivership.

On August 27, 2026 (the “Petition Date”), BioXcel Therapeutics, Inc. (the “Company”) and its subsidiaries OnkosXcel

Therapeutics, LLC and OnkosXcel Employee Holdings, LLC (together with the Company, the “Debtors”) each filed voluntary petitions

for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the

“Court” and such cases, the “Cases”). The Debtors have requested that the Cases be jointly administered under

the caption “In re BioXcel Therapeutics, Inc., et al.” The Debtors will continue to operate their businesses as “debtors-in-possession”

under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. To

ensure its ability to continue operating in the ordinary course of business, the Company has filed with the Court motions seeking a variety

of “first-day” relief (collectively, the “First Day Motions”).

In addition, the Company filed, or is expected to shortly file, with

the Court a motion seeking approval of debtor-in-possession financing (“DIP Financing”) to fund post-petition operations and

costs in the ordinary course. The DIP Financing is expected to be provided by affiliates of Oaktree Capital Management, L.P. and the Qatar

Investment Authority, which are the same parties (or affiliates thereof) that provided prepetition financing to the Company under the

Debtors’ existing Credit Agreement and Guaranty, dated as of April 19, 2022 (as amended through August 24, 2026, the “Prepetition

Credit Agreement”), and to consist of (i) new money term loan commitments in an aggregate principal amount of up to $19 million,

available in two draws: an initial draw of up to $9.5 million upon entry of the interim DIP order and an additional draw of up to $9.5

million upon entry of the final DIP order, and (ii) roll-up loans in an aggregate principal amount of up to $58.25 million, resulting

from the conversion of a portion of the prepetition obligations outstanding under the Prepetition Credit Agreement into obligations under

the DIP Financing on a dollar-for-dollar basis.

The Company’s objective in the Cases is

to maximize value for its stakeholders, which may be achieved through the sale of all or substantially all assets to the highest bidder

or bidders. Additional information about the Cases, including access to Court documents, is available online https://cases.stretto.com/BioXcel,

a website administered by Stretto, a third-party bankruptcy claims and noticing agent. The information on this website is not incorporated

by reference into, and does not constitute part of, this Current Report on Form 8-K.

In connection with the foregoing, the Company appointed

Samir Saleem as the Chief Restructuring Officer (the “CRO”) of the Company to assist with certain executive management, restructuring,

lender relationship management, accounting management, operations support, and communication. The CRO will report to a Strategic Process

Committee of the Board that was appointed pursuant to the Prepetition Credit Agreement in order to evaluate, negotiate, oversee, coordinate

and implement any sale, restructuring or other material transactions, including the Case.

Stalking Horse Asset Purchase Agreement

On August 27, 2026, the Debtors entered into an

asset purchase agreement (the “Stalking Horse APA”) by and among the Debtors, Teva Pharmaceuticals International GmbH, a Swiss

limited liability company (“Teva”), and Teva Pharmaceutical Industries Limited, a company incorporated under the laws of Israel

(solely as guarantor of Teva’s milestone obligations for purposes of Section 9.16 of the Stalking Horse APA).

Pursuant to the Stalking Horse APA, the Company

has agreed to sell, and Teva has agreed to acquire, subject to the terms and conditions contained therein, substantially all of the Debtors’

assets (collectively, the “Assets”), and to assume certain specified liabilities of the Debtors (collectively, the “Liabilities”

and such acquisition of the Assets and assumption of the Liabilities, the “Transaction”) for consideration of upfront cash

in the amount of $57.5 million, assumption of the Liabilities, plus up to $67.5 million of contingent “Development Milestone Payments”

tied to the outcome and timing of the pending sNDA for IGALMI® at-home use (the “sNDA”). Depending on the timing of approval

of the pending sNDA, the Debtors may also be entitled to up to $20 million in Commercial Milestone payments, depending on net sales reaching

certain sales thresholds post-closing. Under the Stalking Horse APA, Teva has agreed to serve as the “stalking horse” bidder

in respect of the Assets, and the Transaction remains subject to higher or otherwise better bids in connection with the auction process

to be conducted by the Debtors in the Cases.

The Transaction, and the designation of Teva as

the stalking horse bidder, is subject to the approval of the Court. As the proposed stalking horse bidder, Teva’s offer to purchase

the Assets and assume the Liabilities, as set forth in the Stalking Horse APA, would serve as the minimum, or floor, bid. On August 27,

2026, the Company filed a motion with the Court seeking authority to sell the Assets to Teva pursuant to Section 363 of the Bankruptcy

Code, subject to higher or otherwise better bids, approval of the proposed bidding procedures, designation of Teva as the stalking horse

bidder for the Assets, certain bid protections for the stalking horse bidder, and a motion requesting a hearing on approval of the bidding

procedures (the “Sale Motion”).

The Stalking Horse APA contains customary representations,

warranties and covenants of the parties for a transaction involving the acquisition of assets from debtors in bankruptcy, and the completion

of the Transaction is subject to a number of customary conditions, which, among others, include the entry of an order of the Court authorizing

and approving the Transaction, the performance by each party of its obligations under the Stalking Horse APA and the material accuracy

of each party’s representations.

The Stalking Horse APA contains customary termination

provisions, including rights exercisable by either party, by the Company alone or by Teva alone upon the occurrence of specified events,

including failure to satisfy specified case milestones, material breach by the other party, failure to consummate the Transaction by October

30, 2026, and the occurrence of certain Court or case-related events adverse to Teva.

The foregoing summary of the Stalking Horse APA

is not complete and is qualified in its entirety by reference to the full text of the Stalking Horse APA, a copy of which will be filed

as an exhibit to an amendment to this Current Report on Form 8-K.

The representations, warranties and covenants set

forth in the Stalking Horse APA have been made only for purposes of the Stalking Horse APA and solely for the benefit of the parties thereto,

and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures made for

the purposes of allocating contractual risk between the parties to the Stalking Horse APA instead of establishing these matters as facts.

In addition, information regarding the subject matter of the representations and warranties made in the Stalking Horse APA may change

after the date of the Stalking Horse APA and do not purport to be accurate as of the date of this Current Report on Form 8-K. Accordingly,

investors should not rely upon the representations and warranties in the Stalking Horse APA as statements of factual information.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K may contain

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,”

“believes,” “expects,” “intends,” “potential,” “projects,” “target,”

“will,” “would” and “future” or similar expressions are intended to identify forward-looking statements.

Forward-looking statements in this report include statements concerning, among other things, the Cases, the Company’s ability to

complete the Transaction and its ability to continue operating in the ordinary course while the Cases are pending, and other statements

that are not historical fact. These statements are based upon the current expectations and beliefs of management and are subject to certain

risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

These risks and uncertainties include, but are not limited to: (i) risks related to the consummation of the Transaction; (ii) potential

adverse effects of the Cases on the Company’s liquidity and results of operations; (iii) the Company’s ability to obtain

timely approval by the Court of the motions filed in the Cases; (iv) objections to the Transaction, the bidding procedures, or other

pleadings filed that could protract the Cases; (v) employee attrition and the Company’s ability to retain senior management and

other key personnel due to the distractions and uncertainties; (vi) the Company’s ability to comply with the restrictions imposed

by the terms and conditions of the Company’s financing arrangements, including the DIP Facility; (vii) the Company’s ability

to maintain relationships with suppliers, vendors, partners, employees and other third parties and regulatory authorities as a result

of the Cases; (viii) the effects of the Cases on the Company and on the interests of various constituents, including holders of the Company’s

common stock; (ix) the Court’s rulings in the Cases, including the approvals of the terms and conditions of the Transaction, and

the outcome of the Cases generally; (x) the length of time that the Company will operate under Chapter 11 protection and the continued

availability of operating capital during the pendency of the Cases; (xi) risks associated with third party motions in the Cases, which

may interfere with the Company’s ability to consummate the Transaction or an alternative transaction; (xii) increased administrative

and legal costs related to the Chapter 11 process; (xiii) exposure to potential litigation, including related to the Transaction, and

inherent risks involved in a bankruptcy process; (xiv) the occurrence of any event, change or other circumstances that could give rise

to the right of the Company or Teva to terminate the Stalking Horse APA; (xv) the possibility that the anticipated benefits of the Transaction

are not realized when expected or at all, including that the Transaction contemplates contingent payments upon the occurrence of milestone

events that may never be achieved; (xvi) the possibility that the Transaction may be more expensive to complete than anticipated; (xvii)

diversion of management’s attention from ongoing business operations and opportunities; (xviii) potential adverse reactions or

changes to business or employee relationships, including those resulting from the bankruptcy proceedings of the Company or announcement

or completion of the Transaction; (xix) the risk that the Company will not realize the anticipated benefits of its reduction in force;

and other risks and uncertainties, including those described in the section entitled “Risk Factors” in the Company’s

most recent annual or quarterly report filed with the Securities and Exchange Commission and in other filings the Company makes with

the Securities and Exchange Commission from time to time. The forward-looking statements herein do not constitute guarantees of future

performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements

speak only as of the date hereof. The Company undertakes no obligation to update the information contained in this Current Report on

Form 8-K to reflect new events or circumstances, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 28, 2026

BIOXCEL THERAPEUTICS, INC.

/s/ Richard Steinhart

By:

Richard Steinhart

Title:

Chief Financial Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

Aug. 27, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 27, 2026

Entity File Number

001-38410

Entity Registrant Name

BioXcel

Therapeutics, Inc.

Entity Central Index Key

0001720893

Entity Tax Identification Number

82-1386754

Entity Incorporation, State or Country Code

Entity Address, Address Line One

555

Long Wharf Drive

Entity Address, City or Town

New

Haven

Entity Address, State or Province

Entity Address, Postal Zip Code

06511

City Area Code

475

Local Phone Number

238-6837

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001

Trading Symbol

BTAI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration